Drug search by name

Rituximab and hyaluronidase human, recombinant Subcutaneous and Autoimmune diseases

Result of checking the interaction of drug Rituximab and hyaluronidase human, recombinant Subcutaneous and disease Autoimmune diseases for safety when used together.

Check result:

Rituximab and hyaluronidase human, recombinant Subcutaneous <> Autoimmune diseases

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

JC virus infection resulting in Progressive Multifocal Leukoencephalopathy (PML) and death can occur in rituximab-treated patients with hematologic malignancies or with autoimmune diseases. Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations. Discontinue rituximab and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.

Rituximab and hyaluronidase human, recombinant Subcutaneous

Generic Name: hyaluronidase / rituximab

Brand Name: Rituxan Hycela

Synonyms: Hyaluronidase and rituximab, Rituximab and Hyaluronidase

What is Rituximab and hyaluronidase human, recombinant Subcutaneous?